Globus Medical, Inc. $GMED Stock Holdings Lowered by Bridge City Capital LLC

Bridge City Capital LLC cut its position in shares of Globus Medical, Inc. (NYSE:GMED) by 27.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 84,082 shares of the medical device company’s stock after selling 31,893 shares during the period. Globus Medical accounts for 2.2% of Bridge City Capital LLC’s holdings, making the stock its 6th biggest position. Bridge City Capital LLC owned about 0.06% of Globus Medical worth $7,341,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in GMED. Bank of Montreal Can boosted its holdings in Globus Medical by 15,317.1% during the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after buying an additional 3,351,380 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Globus Medical by 1,303.9% during the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock worth $117,700,000 after buying an additional 1,908,795 shares in the last quarter. Fuller & Thaler Asset Management Inc. purchased a new stake in Globus Medical during the fourth quarter worth $90,411,000. Norges Bank purchased a new stake in Globus Medical during the fourth quarter worth $89,922,000. Finally, ANTIPODES PARTNERS Ltd boosted its holdings in Globus Medical by 49,020.3% during the third quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock worth $51,034,000 after buying an additional 889,229 shares in the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Globus Medical Stock Performance

NYSE:GMED opened at $80.44 on Friday. The company has a fifty day moving average of $85.77 and a two-hundred day moving average of $88.10. The stock has a market capitalization of $10.92 billion, a PE ratio of 18.71, a P/E/G ratio of 1.66 and a beta of 0.95. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GMED shares. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Piper Sandler reissued an “overweight” rating on shares of Globus Medical in a report on Tuesday. Wells Fargo & Company lowered their price target on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Truist Financial set a $115.00 price target on shares of Globus Medical in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $106.36.

Insiders Place Their Bets

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 18.38% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.